Compare CRSP & TEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSP | TEO |
|---|---|---|
| Founded | 2013 | 1979 |
| Country | Switzerland | Argentina |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.2B |
| IPO Year | 2016 | N/A |
| Metric | CRSP | TEO |
|---|---|---|
| Price | $56.70 | $11.49 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 2 |
| Target Price | ★ $71.50 | $9.60 |
| AVG Volume (30 Days) | ★ 1.8M | 208.2K |
| Earning Date | 02-10-2026 | 11-10-2025 |
| Dividend Yield | N/A | ★ 2.76% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $38,337,000.00 | ★ $4,379,419,485.00 |
| Revenue This Year | N/A | $91.61 |
| Revenue Next Year | $723.84 | $10.21 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 18.69 |
| 52 Week Low | $30.04 | $6.43 |
| 52 Week High | $78.48 | $15.54 |
| Indicator | CRSP | TEO |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 46.21 |
| Support Level | $54.50 | $11.24 |
| Resistance Level | $59.18 | $11.76 |
| Average True Range (ATR) | 2.87 | 0.42 |
| MACD | 0.33 | -0.17 |
| Stochastic Oscillator | 44.03 | 16.38 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Telecom Argentina SA offers its customers quadruple play services, combining mobile telephony services, cable television services, Internet services and fixed telephony services. It also provides other telephone-related services such as international long-distance and wholesale services, data transmission and IT solutions outsourcing and install, operate and develop cable television and data transmission services. The company provides services in Argentina (mobile, cable television, Internet and fixed and data services), Paraguay (mobile, Internet and satellite TV services), Uruguay (cable television services), the United States (fixed wholesale services) and Chile (Cybersecurity services and products).